Cutaneous T-Cell Lymphoma Treatment: Case Series of Combination Therapy With Intralesional Injections of 5-Fluorouracil and Topical Imiquimod.
Citation: Cutis. 111(1):E19-E25, 2023 Jan.PMID: 36947768Institution: MedStar Washington Hospital CenterDepartment: Dermatology | Medical Dermatology ResidencyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Lymphoma, T-Cell, Cutaneous | *Skin Neoplasms | Fluorouracil | Humans | Imiquimod/tu [Therapeutic Use] | Injections, Intralesional | Lymphoma, T-Cell, Cutaneous/dt [Drug Therapy] | Skin Neoplasms/pa [Pathology]Year: 2023Local holdings: Available online through MWHC library: 2000 - 2010, Available in print through MWHC library: July 1998 - 2007ISSN:- 0011-4162
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | Available |
Available online through MWHC library: 2000 - 2010, Available in print through MWHC library: July 1998 - 2007
Cutaneous T-cell lymphoma (CTCL) is a chronic form of skin cancer. Skin-directed therapies rarely achieve complete clearance of lesions, and recurrences are frequent. In this case series, 9 patients with stage IA to IVA2 CTCL received intralesional (IL) therapy with 5-fluorouracil (5-FU) and imiquimod (IMQ) cream 5% daily to recalcitrant plaques and tumors. All 9 patients attained a complete response (CR) with no recurrences reported and no severe side effects. We find that combination IL 5-FU and IMQ cream 5% daily is a well-tolerated, effective, and durable skin-directed therapy for recalcitrant plaques and tumors in CTCL.
English